Terns Pharmaceuticals accepted a deal with Merck that values the leukemia specialist at a level about 15% below an earlier bid, according to regulatory filings. The revised outcome comes amid competitive contention from multiple parties, with Merck ultimately completing the purchase after clinical data shifted the negotiating landscape. The transaction reflects how late-stage or clinical-readout dynamics can reshape valuations in the biopharma M&A cycle. Investors will monitor whether Merck’s integration plan leverages Terns’ lead assets as Merck rationalizes its hematology pipeline. For target owners, the case is a reminder that bid protection can erode when data and timelines change quickly, especially in oncology where clinical signals carry weight for pricing.